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Nocardiosis is increasingly being diagnosed due to a growing population of 31 
immunocompromised hosts and improvements in the detection of Nocardia 32 
species in clinical laboratories.  Historically, sulphonamides have been the 33 
first-line therapy for the treatment of nocardiosis, but sulphonamides tend to 34 
have high rate of drug allergy in clinical settings.  In this report, we 35 
described a disseminated N. farcinica infection occurred in a patient with 36 
myasthenia gravis, who suffered from multiple drug allergies and was 37 
successfully treated using linezolid.  We undertook a review of literature of 38 
previously reported cases of nocardiosis treated with linezolid.  To date, only 39 
15 cases of nocardiosis treated with linezolid have been published.  All cases 40 
exhibited long-term tolerance of linezolid and 14 out of 15 cases showed 41 
either an improvement in or complete clearance of the infection.  According 42 
to the literature review, linezolid is an attractive alternative to 43 
trimethoprim-sulfamethoxazole for the treatment of disseminated 44 





Nocardiosis is increasingly being diagnosed due to a growing population of 48 
immunocompromised hosts and improvements in the detection and 49 
identification of Nocardia species in clinical laboratories.  However, none of 50 
the reported cases have been diagnosed concomitantly with myasthenia 51 
gravis (MG), making this the first reported case of its kind.  Data regarding 52 
prognosis in nocardiosis are highly variable, with published mortality rates 53 
ranging from 14% to 40% [1-3]. In cases of disseminated infection, mortality 54 
rates may even approach 100%. 55 
In this report, we describe a disseminated infection (with bacteraemia, 56 
multilobar pneumonia, and kidney and brain abscesses) caused by N. 57 
farcinica that occurred in a patient with MG. This patient suffered from 58 
multiple drug allergies and was successfully treated using linezolid.  In 59 
addition reported cases of nocardiosis treated with linezolid were reviewed. 60 
 61 
Case report 62 
A 59-year-old woman was admitted to Kyoto University Hospital with 63 
malaise, cough and stomatitis in October 2010.  She had been diagnosed 64 
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with myasthenia gravis (MG) one year prior to admission and had received 65 
immunosuppressive treatment, including prednisolone ( 15mg once daily ) 66 
and tacrolimus.  Upon admission, she appeared acutely ill and complained a 67 
shortness of breath with body movement.  Physical examination revealed a 68 
body temperature of 36.5 °C, a respiratory rate of 24 breaths per minute, 69 
blood pressure of 71/52 mm Hg, and a heart rate of 106 beats per minute. 70 
Diffuse crackles were audible in both upper lungs.  Laboratory tests 71 
revealed hemoglobin of 8.0 mg/dL, a white blood cell count of 19,100/mm3, 72 
platelet count of 465 x 109 /L, total protein of 4.4 g/dL, albumin of 2.4 g/dL, 73 
C-reactive protein of 10.9 mg/dL, and IgG of 363 mg/dL.  Chest radiographs 74 
and computed tomography (CT) scanning showed extensive diffuse bilateral 75 
reticulonodular infiltrates.  An abdominal CT showed an abscess in the 76 
right kidney, whereas a head CT did not reveal any abnormalities.  Neither 77 
vegetation nor valvular thickening was detected during transthoracic 78 
echocardiography, which ruled out infective endocarditis.  Two sets of blood 79 
cultures and a sputum culture were obtained, and piperacillin-tazobactam 80 
(TZP) 4.5g q8h and ciprofloxacin (CIP) 300mg q12h were started based on a 81 
presumptive diagnosis of severe healthcare-associated, community-acquired 82 
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pneumonia and pyogenic kidney abscesses.  Gram staining of the sputum 83 
showed Gram-positive filaments suggestive of Nocardia spp. or Actinomyces.  84 
TZP and CIP were changed to imipenem-cilastatin (IPM) 0.5g q6h and 85 
trimethoprim-sulphamethoxazole (TMP) 4 tablets orally q12h on the fourth 86 
day, due to a deterioration in respiratory function.  On the seventh day, the 87 
blood and sputum cultures collected at admission grew a “Corynebacterium 88 
“ species, based on identification using a VITEK 2 system (bioMérieux, 89 
Marcy l'Etoile, France).  This culture was further identified as N. farcinica 90 
via sequencing analysis of the 16S rRNA gene of the isolates and the 91 
phenotype of the bacteria.  The isolate was susceptible to cefotaxime ( <= 92 
2.0 ug ml-1), AMK ( < 1.0 ug ml-1 ), CPFX ( 1.0 ug ml-1 ), IPM ( <= 0.5 ug ml-1 ), 93 
minocycline (MINO) (1.0 ug ml-1), and resistant to gentamicin ( 32 ug ml-1 ), 94 
TZP ( 128.0 ug ml-1).  We changed IPM and TMP to MINO on the eighteenth 95 
day due to a generalised skin rash and a facial flushing that seemed to be 96 
caused by a drug allergy.  Accordingly, we attempted desensitisation to TMP.  97 
Cyclosporine was started on the thirty-sixth day as a treatment for MG, as 98 
the physical signs of systemic illness were gradually improving. 99 
On the fifty-seventh day, the patient’s fever rose to 38 °C.  She was free of 100 
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neurological symptoms, but multiple brain abscesses were detected by 101 
magnetic resonance imaging, and an abdominal CT showed enlargement of 102 
the abscess on the right kidney.  We tried meropenem and amikacin, but 103 
infectious symptoms were not improved.  Linezolid 600mg q12h was started, 104 
with subsequent improvement in the brain and right kidney abscesses.  105 
Mild thrombocytopenia developed on the ninety-seventh day (the platelet 106 
count decreased from 465 x 109/L to 121 x 109/L), and linezolid therapy was 107 
changed to TMP.  Any side effect other than mild thrombocytopenia did not 108 
occur during 38-day course of linezolid therapy.  The patient was discharged 109 
on the one hundred twentieth day and was followed up at an outpatient 110 
clinic without a worsening of infectious symptoms or a severe adverse 111 
reaction to TMP. 112 
 113 
Disucussion 114 
We reported herein a case of disseminated N. farcinica infection in which the 115 
causative organism was misidentified as a Corynebacterium spp. and a drug 116 
allergy to the first-line therapy for nocardiosis altered antibiotic selection.   117 
Nocardia spp. can be cultured on most bacterial media, and thus a high 118 
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degree of suspicion is needed for diagnosis of nocardiosis.  This includes 119 
consideration of the patient’s underlying illnesses and unique bacterial 120 
characteristics identified via Gram and Ziehl-Neelsen staining.  In the early 121 
phase of growth on standard media, the organisms may resemble 122 
‘diphtheroid’ bacilli, which commonly contaminate samples.  This may lead 123 
to an incorrect identification of patient cultures.  In the case presented here, 124 
an automatic identification system misidentified the bacilli as 125 
Corynebacterium spp.; however, actinomycosis was strongly suspected due to 126 
the patient’s background and clinical progression.  Therefore, we performed 127 
sequencing analysis of the 16S rRNA gene of the isolates and made a 128 
confirmatory diagnosis using the biological characteristics of the cultured 129 
bacteria.  Culture contaminants are commonplace, and invasive Nocardia 130 
infections are rare.  Therefore, close collaboration between clinicians and 131 
clinical laboratories is necessary for the optimal diagnosis and treatment of 132 
patients.   133 
Historically, sulphonamides have been the first-line therapy for the 134 
treatment of nocardiosis, with TMP being the most commonly used 135 
treatment.  Sulpha drugs may reduce the mortality rate when used alone or 136 
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in combination with other antimicrobials [1,2].  In an immunocompromised 137 
patient with severe, progressive infection or central nerve system 138 
involvement, treatment should involve a combined therapy of either TMP 139 
and a bactericidal agent or a combination of imipenem and amikacin [1-3].   140 
In the current case, we decided to treat with amikacin (with close monitoring 141 
of neurological status) and IPM despite the patient’s diagnosis of MG, due to 142 
the emergence of a drug allergy to TMP.  Unfortunately, an allergic reaction 143 
to IPM also occurred, and the renal abscess worsened; therefore, we 144 
administered linezolid as a last line of defence.   145 
Linezolid crosses the blood-brain barrier and has excellent bioavailability.  146 
In vitro activity of linezolid against Nocardia spp. was observed in several 147 
studies.  Brown-Elliott et al. tested 140 clinical isolates by broth 148 
microdilution and demonstrated that linezolid concentrations of 4 ug/mL 149 
inhibited 90% isolates (90% minimum inhibitory concentration), which is in 150 
susceptible range according to the proposed Clinical and Laboratory 151 
Standard Institute MIC breakpoint. [4]  In another study testing 93 152 
Nocardia isolates by the Etest method, all isolates were susceptible to 153 
linezolid. [5]  Thus, it is an attractive alternative treatment for central 154 
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nervous system nocardiosis, despite limited clinical evidence to support this 155 
claim.   156 
Fifteen cases of nocardiosis treated with linezolid have been published to 157 
date.(Table)[6-15]  Linezolid has a well-documented short-term adverse 158 
effect profile, with headache and diarrhoea most commonly seen; however, 159 
its long-term safety profile (>28 days) has not been extensively studied.  In 160 
9 of these cases, linezolid was selected due to a lack of tolerance to TMP or 161 
beta-lactams, and 2 cases were due to multidrug resistant Nocardia spp.  162 
All cases exhibited long-term tolerance of linezolid (median 120; range 163 
30-720 days) and 14 out of 15 cases showed either an improvement in or 164 
complete clearance of the infection.  Whether linezolid treatment is superior 165 
to TMP or beta-lactam treatment is still unknown; however, this agent may 166 
be a last resort for nocardiosis.  Information on efficacy and outcomes 167 
similar to this report will be important in treating Nocardia spp. infections, 168 
due to the need for an extended course of treatment and the relative lack of 169 
available data.   170 
Although reviews of therapy for Nocardia infections recommend TMP as the 171 
therapeutic drug of choice, sulphonamide-resistant Nocardia infections have 172 
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been reported in many countries, including the United States, Japan, France 173 
and Britain[16,17].  TMP susceptibility varies geographically, and TMP 174 
resistance ranges from a low of 32% for N. brevicatena to 93% for N. 175 
farcinica .  Multidrug resistance may also occur with N. farcinica, and thus 176 
susceptibility varies among Nocardia species as well.  In addition, Tremblay 177 
et al. recently reported the high frequency of isolation of N. farcinica from 178 
specimens that indicated invasive disease (such as brain or lung biopsies and 179 
blood) [16].  Given the preponderance of invasive N. farcinica infection and 180 
the frequent non- susceptibility of isolates to TMP, this drug may no longer 181 
be the first choice in some regions.   182 
Publication bias is an important consideration, as some authors hesitate to 183 
publish or present cases with poor outcomes.  Another limitation is that the 184 
published evidence regarding the efficacy and safety of linezolid in patients 185 
with nocardiosis is derived solely from a small subset of case reports.  186 
Although the incidence of nocardiosis is thought to be on the rise, it remains 187 
a rare opportunistic infection.  Thus, it is difficult to establish the use of 188 
linezolid in the therapeutic regimen for nocardiosis through randomised 189 
controlled trials. 190 
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Additional accumulation of case reports regarding the use of linezolid in 191 
Nocardia infections will be of use to clinicians and patients suffering from 192 
disseminated nocardiosis. 193 
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2 29/F SLE Disseminated  N. asteroides ADRs 
Cure (followed 





3 45/M Silicosis/steroid Disseminated  N. asteroides ADRs Cure None 365 
[8] 




Cure Anemia 90 
















7 6/M CGD Lung N. asteroides 
Clinical 
failure 
Cure None 790 
8 9/M CGD Disseminated  NA ADRs Cure None 365 










Brain abscesses N. farcinica 
Clinical 
failure 
Cure Anemia 60 [10] 
11 37/M SLE Brain abscesses N. asteroides 
Adjunctive 
therapy 
Improvement  NA NA [11] 










Lung N. asteroides ADRs Improvement None 36 [13] 
14 66/F Psoriasis Disseminated  N. farcinica 
Multidrug 
resistance 
Unchanged None NA [14] 











16 59/F MG Disseminated  N. farcinica ADRs 
Cure (followed 







NA = not available; ADR = adverse drug reaction; SLE = systemic lupus erythemtatotes; CGD = chronic granumatous disease; MG = 
myasthenia gravis 
